Rising Pharma Holdings Inc. recalls four lots of 5 mg cetirizine hydrochloride allergy tablets after a pharmacy tech noticed possible cross-contamination with ranitidine, posing life-threatening risks to hypersensitive individuals.
Recent studies using FDA Adverse Event Reporting System data have identified drug-associated cardiovascular risks, pediatric dry eye, and venlafaxine adverse effects. Findings highlight the importance of pharmacovigilance monitoring.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07472413 |
Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project |
NOT_YET_RECRUITING | PHASE3 |
